NCT07419893 Germline Genetic Testing of the TP53 Gene
| NCT ID | NCT07419893 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | TP53 Gene Mutation |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,940 participants |
| Start Date | 2026-01-29 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,940 participants in total. It began in 2026-01-29 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.
Eligibility Criteria
Inclusion Criteria: * Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO; * Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used; * Have provided written informed consent for participation in scientific research. Exclusion Criteria: * Absence of signed informed consent for participation in scientific research.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07419893 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying TP53 Gene Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07419893 currently recruiting?
Yes, NCT07419893 is actively recruiting participants. Contact the research team at mariarosaria.calvello@ieo.it for enrollment information.
Where is the NCT07419893 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT07419893 clinical trial?
NCT07419893 is sponsored by European Institute of Oncology. The trial plans to enroll 1,940 participants.